Company Overview
Achieve Life Sciences, Inc. operates as a late-stage pharmaceutical entity dedicated to the development and commercialization of cytisinicline, a plant-based alkaloid designed to address nicotine independence. This core product interacts with nicotine receptors in the brain, offering a therapeutic solution specifically for smoking cessation across key markets including Canada, the United States, and the United Kingdom. The company functions within the Healthcare sector and the Biotechnology industry, positioning itself at the intersection of pharmaceutical innovation and public health solutions. Its financial scale is characterized by a market capitalization of $150.12M, while reported annual revenue and employee count are not disclosed in the current financial data. These valuation metrics indicate that the market assesses the company's position based on its late-stage asset potential rather than current profit generation or workforce size, reflecting a typical capital structure for a biotechnology firm focused on bringing a single proprietary therapy to market.
Financial Health
The company reports a net income of $-54,648,000 and an EBITDA of $-54,652,000, while revenue figures for the trailing twelve months are not available in the provided data. The substantial negative net income relative to the reported EBITDA suggests a significant cost structure burden, likely driven by the high operational expenses typical of late-stage pharmaceutical development and commercialization efforts where revenue has not yet offset these costs. Free cash flow stands at $-37,222,876, indicating that the company is burning through capital reserves to fund its operations and development pipeline, which limits immediate financial flexibility but is common for growth-stage biotechs. All three margin metrics—the gross margin, operating margin, and profit margin—are recorded at 0.0%, which reflects a pre-profitability status where the company has not yet generated sufficient revenue to cover variable and fixed costs to achieve positive margins. The balance sheet shows a cash position of $36.40M against total debt of $14.95M, resulting in a debt-to-equity ratio of 69.48, which suggests a leveraged balance sheet where debt obligations are substantial relative to equity but are partially offset by significant cash holdings. The current ratio is 4.39, indicating a strong short-term liquidity position where current assets are more than four times current liabilities, providing a buffer against immediate payment obligations. Return on Equity is -257.7% and Return on Assets is -85.3%, revealing that management effectiveness is currently measured by the depletion of shareholder and asset value rather than the generation of returns, a metric expected for entities in the development phase that have not yet achieved commercial breakeven.
Valuation Assessment
Valuation metrics for Achieve Life Sciences, Inc. present a complex picture typical of loss-making biotechnology companies, with a forward P/E of -2.69 and a trailing P/E ratio that is not calculable due to negative earnings. The negative forward P/E implies that the market is pricing the stock based on future expectations of earnings turnaround or asset value rather than current profitability, while the absence of a positive trailing P/E confirms the company's current unprofitable status. The price-to-book ratio is 6.98, indicating that the market values the company at nearly seven times its book value, which suggests a significant premium placed on the intellectual property and pipeline potential of cytisinicline despite the lack of current earnings. Alternative valuation measures such as the price-to-sales ratio and EV/EBITDA are also not available or negative at -2.36, respectively, further emphasizing that traditional valuation multiples are not applicable in their standard form for a company with no revenue and negative earnings. The stock has traded between a 52-week low of $1.84 and a 52-week high of $6.03, providing a reference range for price volatility over the last year. The beta value is not available, preventing a direct comparison of price volatility relative to the broader market index.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are not available due to the lack of historical revenue data in the trailing twelve months, making it impossible to calculate growth rates or determine if earnings are growing faster or slower than revenue. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning it does not distribute any portion of its earnings to shareholders. Instead of paying dividends, the company reinvests its earnings, which are currently negative, into research and development to advance cytisinicline toward commercialization and market penetration in the specified regions. The overall growth and income profile is defined by a reliance on capital markets or cash reserves to fund growth initiatives rather than generating current cash flow or providing income to investors through dividends.